Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:TRIL

Trillium Therapeutics (TRIL) Stock Price, News & Analysis

Trillium Therapeutics logo

About Trillium Therapeutics Stock (NASDAQ:TRIL)

Key Stats

Today's Range
$18.44
$18.44
50-Day Range
$17.50
$18.44
52-Week Range
$5.80
$20.96
Volume
8 shs
Average Volume
1.87 million shs
Market Capitalization
$1.94 billion
P/E Ratio
29.74
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Receive TRIL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

TRIL Stock News Headlines

Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners
Trump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…
Leukemia Therapeutics Global Market Report 2023
See More Headlines

TRIL Stock Analysis - Frequently Asked Questions

Trillium Therapeutics Inc. (NASDAQ:TRIL) announced its quarterly earnings results on Thursday, November, 18th. The biotechnology company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.01.

Based on aggregate information from My MarketBeat watchlists, some other companies that Trillium Therapeutics investors own include NVIDIA (NVDA), CannaPharmaRX (CPMD), FuelCell Energy (FCEL), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and Advanced Micro Devices (AMD).

Company Calendar

Last Earnings
11/18/2021
Today
11/15/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TRIL
Fax
N/A
Employees
33
Year Founded
N/A

Profitability

Net Income
$-59,350,000.00
Pretax Margin
-113,720.92%

Debt

Sales & Book Value

Annual Sales
$150,000.00
Price / Sales
12,907.39
Book Value
$2.56 per share

Miscellaneous

Free Float
95,440,000
Market Cap
$1.94 billion
Optionable
Optionable
Beta
2.08
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (NASDAQ:TRIL) was last updated on 11/15/2024 by MarketBeat.com Staff
From Our Partners